2024年12月23日 · Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens, such as viruses like SARS-CoV-2. The authorized dose for REGEN-COV for...

REGEN‑COV remains authorized for the treatment of mild-to-moderate COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID‑19, including hospitalization or death.

Regen-Cov is usually given as only one dose as soon as possible after you are exposed to or test positive for COVID-19, or within 10 days after the start of symptoms. You may need additional monthly doses if you continue to be exposed to COVID-19.

2021年9月29日 · In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients...

2022年1月22日 · The FDA authorized REGEN-COV for the treatment of mild-to-moderate COVID-19 in people aged 12 years and older who are at high risk of developing severe COVID-19. This includes people who are at high risk of being hospitalized or dying.

Regen-Cov package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

REGEN-COV is investigational because it is still being studied. There is limited information known about the safety and effectiveness of using REGEN-COV to treat people with COVID-19 or to...

2024年12月16日 · REGEN-COV is a combination of two monoclonal antibodies (casirivimab and imdevimab) designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19.

2023年7月26日 · Casirivimab and imdevimab (REGEN-COV) are investigational drugs approved for use under EUA and clinical trials are ongoing to evaluate side effects.

2021年8月4日 · REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among...